DZ-2384

DZ-2384 is a potent microtubule-targeting agent. DZ-2384 increases the rescue frequency and preserves the microtubule network in nonmitotic cells and primary neurons. DZ-2384 acts synergistically with anti-CTLA-4 immunotherapy in Taxane-sensitive and Taxane-resistant xenograft murine models of triple-negative breast cancer (TNBC) . DZ-2384 exhibits potent antitumor activity in adult acute lymphocytic leukemia (ALL) models. DZ-2384 can be used for cancer research, such as TNBC and ALL[1][2].

Product Specifications

CAS Number

[1403850-91-8]

UNSPSC

12352005

Target

Microtubule/Tubulin

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

FC1=CC=C2C([C@@]34C5=C(C6=NC(CO)=CO6)N=C([C@@H](NC([C@@H](NC([C@@H](O)C(C)C)=O)CC7=CC=C(O[C@@]4([H])N2)C3=C7)=O)C(C)(C)C)O5)=C1

Molecular Formula

C34H36FN5O7

Molecular Weight

645.68

References & Citations

[1]Wieczorek M, et al. The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med. 2016 Nov 16;8 (365) :365ra159.|[2]Bernier C, et al. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs. 2018 Sep;29 (8) :774-785.